Pays: Indonésie
Langue: indonésien
Source: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
PEGFILGRASTIM
INDOFARMA - Indonesia
PEGFILGRASTIM
6 MG
CAIRAN INJEKSI
BOX OF 1 BLISTER @ 1 PREFILLED SYRINGE @ 0,6 ML
BIOCON LIMITED - India
2021-02-22
DISETUJUI OLEH BPOM 4 FEBRUARI 2021 ID REG: EREG10021811900022 SUMMARY OF PRODUCT CHARACTERISTICS FULPHILA ™ (PEGFILGRASTIM) PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR INJECTION (PEG-GCSF INJECTION) 6 MG/0.6 ML FOR SUBCUTANEOUS USE ONLY STERILE SOLUTION - NO PRESERVATIVE COMPOSITION Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 ml solution for injection. The concentration is 10 mg/ml based on protein only**. *Produced in _Escherichia _ _coli_ cells by recombinant DNA technology followed by conjugation with polyethylene glycol (PEG). ** The concentration is 20 mg/ml if the PEG moiety is included. The potency of this product should not be compared to the potency of another pegylated or non-pegylated protein of the same therapeutic class. EXCIPIENT(S) WITH KNOWN EFFECT Each pre-filled syringe contains 30-mg sorbitol For a full list of excipients, see section LIST OF EXCIPIENTS. PHARMACEUTICAL FORM Solution for injection in a pre-filled syringe (injection). Clear, colourless solution for injection. PHARMACOLOGICAL PROPERTIES PHARMACODYNAMIC PROPERTIES Pharmacotherapeutic group: immunostimulants, colony stimulating factor; ATC Code: L03AA13. Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Pegfilgrastim is a covalent DISETUJUI OLEH BPOM 4 FEBRUARI 2021 ID REG: EREG10021811900022 conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20 kd polyethylene glycol (PEG) molecule. Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Similarly, to filgrastim, neutrophils produced in response to pegfilgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As with other haematopoietic growth fac Lire le document complet